财务数据和关键指标变化 - 公司第三季度总销售额增长7%,调整后EBITDA和调整后净收入均增长9% [25][28][29] - 动物保健业务销售额增长10%,其中疫苗销售增长26%,MFA和其他业务增长16%,但营养特产品销售下降11% [31][32][33] - 矿物营养和性能产品业务销售有所改善,但仍有下降 [34][35] - 年初至今,公司总收入增长3%,调整后EBITDA下降3% [19][20] 公司战略和发展方向 - 公司宣布收购Zoetis的MFA业务,将增强公司的物种和产品组合,提高盈利能力和偿债能力 [13][14][15][21][22] - 公司将继续投资于增长较快的疫苗、营养特产品和宠物产品业务 [15][53][60] - 公司将通过偿还债务来降低财务杠杆,并保持现有的股息政策 [54][55][56] 管理层对经营环境和未来前景的评论 - 公司对动物保健业务的持续增长以及矿物营养和性能产品业务的改善持乐观态度 [16][40] - 公司确认了2024财年的收入、调整后EBITDA和调整后每股收益的指引 [38][39] 行业竞争 - 公司收购Zoetis的MFA业务将增强其在无抗生素饲料添加剂市场的竞争力 [61][62]

Phibro Animal Health Corporation Webcast and Conference Call May 9, 2024 U.S. toll-free ...

Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance TEANECK, N.J., May 8, 2024 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2024 and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) - Net sales o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13-184 ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q2 2024 Earnings Conference Call February 8, 2024 9:00 AM ET Company Participants Richard Johnson - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Daniel Bendheim - Executive Vice President, Corporate Strategy Glenn David - Incoming Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Mikaela Franceschina - Barclays Brian Wright - Roth MKM Operator Hello and thank you for standing by. My name ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13- ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q1 2024 Earnings Conference Call November 9, 2023 9:00 AM ET Company Participants Daniel M. Bendheim - EVP, Corporate Strategy Jack C. Bendheim - Chairman, President & CEO Richard G. Johnson - Interim CFO Conference Call Participants Unidentified Analyst - Barclays Michael Ryskin - Bank of America Securities Brian Wright - ROTH MKM Partners Linda Bolduc - Morgan Stanley Operator Hello, and thank you for standing by. My name is Regina, and I will be your confere ...

Phibro Animal Health Corporation Financial Results Fiscal Year 2024 First Quarter Ended September 30, 2023 Webcast and Conference Call November 9, 2023 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: [3927884] 1 November 9, 2023 Webcast & Conference Call Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and le ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13 ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2023 Results Conference Call August 31, 2023 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Donny Bendheim - Director and Executive Vice President, Corporate Strategy Conference Call Participants Brian Wright - ROTH MKM Michael Ryskin - Bank of America Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your operator today. At this ti ...